APA (7th ed.) Citation

E, G., B, G., R, M., A, P., B, H., & I, M. (2020). The cardiovascular safety of antiobesity drugs-analysis of signals in the FDA Adverse Event Report System Database. International journal of obesity (2005), 44(5), 1021. https://doi.org/10.1038/s41366-020-0544-4

Chicago Style (17th ed.) Citation

E, Gorelik, Gorelik B, Masarwa R, Perlman A, Hirsh-Raccah B, and Matok I. "The Cardiovascular Safety of Antiobesity Drugs-analysis of Signals in the FDA Adverse Event Report System Database." International Journal of Obesity (2005) 44, no. 5 (2020): 1021. https://doi.org/10.1038/s41366-020-0544-4.

MLA (9th ed.) Citation

E, Gorelik, et al. "The Cardiovascular Safety of Antiobesity Drugs-analysis of Signals in the FDA Adverse Event Report System Database." International Journal of Obesity (2005), vol. 44, no. 5, 2020, p. 1021, https://doi.org/10.1038/s41366-020-0544-4.